Tone mix
Week by week 51 weeks
Share of Celcuity Inc. Common Stock's 185 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Apr 6, 2026 · tone +100Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally+72
- Week of Aug 4, 2025 · tone 0Celcuity : Corporate Presentation (Celcuity Investor Presentation V.6.15 Final)-71
- Week of Apr 13, 2026 · tone +99Celcuity, Inc. (NASDAQ:CELC) Receives $109.88 Average PT from Analysts+68
- Week of Oct 19, 2026 · tone +100Celcuity Shares Climb Nearly 8% as Cantor Fitzgerald Backs Breast Cancer Drug Maker Ahead of Key ESMO Data+68
- Week of Apr 27, 2026 · tone +100Celcuity Inc. (CELC): Likely Leader in Next Generation of Breast Cancer Treatments+66
- Week of Jun 8, 2026 · tone +100Celcuity Breast Cancer Study Hits Goal as Gedatolisib Regimens Double Disease-Control Time+58
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Celcuity Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 3 | +33 |
| Last 30 sessions | 7 | +36 |
| Last 90 sessions | 34 | +16 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 26, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.manilatimes.net · 1 outletCelcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026Neutral
- www.manilatimes.net · 1 outletCelcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026 | www.manilatimes.net | 1 | Neutral |
| Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026 | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.ibtimes.com.au · 1 outletCelcuity Shares Climb Nearly 8% as Cantor Fitzgerald Backs Breast Cancer Drug Maker Ahead of Key ESMO DataPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Celcuity Shares Climb Nearly 8% as Cantor Fitzgerald Backs Breast Cancer Drug Maker Ahead of Key ESMO Data | www.ibtimes.com.au | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 2, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.finanznachrichten.de · 1 outletCelcuity Inc.: Celcuity Appoints David Gryska To Its Board Of DirectorsNeutral
- www.manilatimes.net · 1 outletCelcuity Appoints David Gryska To Its Board Of DirectorsNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Celcuity Inc.: Celcuity Appoints David Gryska To Its Board Of Directors | www.finanznachrichten.de | 1 | Neutral |
| Celcuity Appoints David Gryska To Its Board Of Directors | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 1, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.aol.com · 3 outletsWhy Celcuity Stock Was a Winner on WednesdayPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Why Celcuity Stock Was a Winner on Wednesday | www.aol.com | 3 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, September 28, 2026
1 headline, average tone +51: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.insidermonkey.com · 1 outletIs Celcuity (CELC) Stock a Buy? - Insider MonkeyPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Is Celcuity (CELC) Stock a Buy? - Insider Monkey | www.insidermonkey.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Celcuity Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.